title: Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial.
abstract: Sixty consecutive patients with chronic hepatitis C were included in a randomized controlled trial of recombinant human interferon-alpha 2a vs. no treatment. Treated patients received tapering doses of interferon thrice weekly for 1 yr. Twenty treated cases (66.7%) normalized serum aminotransferase levels within the first 4 mo of treatment, but reactivation or breakthrough frequently occurred afterward (20% in both cases). Only one of the untreated patients showed spontaneous normalization of serum aminotransferase levels. Liver histology did not improve in patients without a biochemical response or with breakthrough during therapy, whereas it did not worsen in long-term responders and reactivating patients. Lack of response does not appear to be related to serum interferon antibodies, although their early appearance is more frequent in patients who showed reactivation later on. No biochemical parameter was found to be predictive for positive response to treatment. Antibody to c100 became negative in 62.5% of long-term responders, whereas no change was recorded in other treated patients or controls. Reactivation and breakthrough often occur during treatment, and further studies are needed to determine the most effective schedule (dose and time) of interferon treatment. Loss of c100 antibody during therapy may be a marker of long-term maintenance of response to interferon therapy.
authors.affiliation: Istituto di Medicina Clinica-Clinica Medica 2, University of Padua, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Diodati
authors.forename: P
authors.initials: P
authors.lastname: Bonetti
authors.forename: F
authors.initials: F
authors.lastname: Noventa
authors.forename: C
authors.initials: C
authors.lastname: Casarin
authors.forename: M
authors.initials: M
authors.lastname: Rugge
authors.forename: S
authors.initials: S
authors.lastname: Scaccabarozzi
authors.forename: A
authors.initials: A
authors.lastname: Tagger
authors.forename: L
authors.initials: L
authors.lastname: Pollice
authors.forename: F
authors.initials: F
authors.lastname: Tremolada
authors.forename: C
authors.initials: C
authors.lastname: Davite
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D002908:Chronic Disease; D005260:Female; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D018937:Hepatitis C Antibodies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012008:Recurrence; D012074:Remission Induction; D000637:Transaminases / Q000097:blood
chemical_list: D000906:Antibodies; D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000637:Transaminases